Pulmonology

Study show blocking FOXM1 can reduce the activation of fibroblasts as well as the process of idiopathic pulmonary fibrosis (IPF) itself.

Rare Disease Report sat down with AdAlta CEO Sam Cobb to discuss the impetus for the redesign of AD-214, and what it means for those in the idopathic pulmonary fibrosis.

Adding an anti-muscarinic to inhaled corticosteroid reduces asthma exacerbations, but possibly not more than other combinations.

The discovery could have researchers reconsidering treatment routes for pediatric patients.

A Rare Pediatric Disease designation was granted by the U.S. FDA this morning to Cellectar Biosciences for CLR 131, intended for the treatment of neuroblastoma.

In total, 35% of all HCPs polled responded that the inhalation device is “highly important” when determining medication for a newly diagnosed, stable patient with COPD.

The 10,000-plus participant IMPACT study reported the triple-combination therapy fared better in exacerbation reduction than FF/VI or FF/UMEC.

At the most recent American Lung Association LUNGFORCE expo, RDR sat down with Carly Ornstein to discuss the new resources made available by the ALA to individuals affected by lung fibrosis.

This morning, Galapagos announced the design of its global Phase 3 program of GLPG1690 in patients with idiopathic pulmonary fibrosis (IPF).

Three lung function trajectory categories were linked to were to 75% of COPD cases in a same-aged patient group by age 53.

The device reduces ischemic time in lung transplantation while enabling longer, safe out-of-body time of the allograft.

The findings indicate the potential for a clinically meaningful improvement and stabilization of lung function.

Early this morning, Reviva Therapeutics announced that the U.S. Food and Drug Administration has granted orphan drug designation to its clinical stage drug candidate RP5063, in development for the treatment of idiopathic pulmonary fibrosis.

A component in inflammatory pathogenesis including airway inflammation could serve as a biomarker in non-eosinophilic asthma.

Many physicians suggest upping a child’s dose of inhaled corticosteroids at the first symptoms of an asthma flare-up, but more research suggests the increased dosage makes no difference.

Lower respiratory infections account for 78.8% of all infectious disease-related deaths, while also reporting the widest absolute mortality inequality among US counties.

Insmed Incorporated announced that it has submitted its New Drug Application for amikacin liposome inhalation suspension (ALIS) to the U.S. FDA.

Clinical data from an ongoing Phase 2 study of PBI-4050 shows that the drug provides a clear clinical benefit in patients with Alstrom syndrome.

At the 16th International Symposium on Amyloidosis, Alnylam presented results from the APOLLO Phase 3 study of patisiran, which targets transthyretin in hATTR amyloidosis.

A new study helps explain why African-American and Puerto Rican children don’t respond as well to the common asthma drug, albuterol.

The first-of-its-kind research links inhaled corticosteroids to adrenal suppression in asthma and chronic obstructive pulmonary disease patients who have a genetic variant in the PDGFD gene.

A Phase 2a clinical study evaluating Molgradex was recently initiated by Savara, Inc. The study intends to evaluate the reduction of sputum samples without growth of non-tuberculosis mycobacteria during the treatment period.

The survey estimates from the National Center for Health Statistics report that more people are vaccinating for flu and testing for HIV.

The therapy was approved on the evidence of a pivotal phase 3 clinical development program which tested the efficacy of the inhibitor versus placebo in 926 adult patients.